Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea - Full Text View

Sponsor:	Viborg Hospital
Collaborator:	Nielsen, Jens OD, M.D.
Information provided by:	Viborg Hospital
ClinicalTrials.gov Identifier:	NCT00452855

Purpose

The purpose of this study is to determine whether sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia concerning post- operative nausea and vomiting.

Condition	Intervention
Nausea Vomiting	Procedure: Sevoflurane-remifentanil anaesthesia

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery

Resource links provided by NLM:

MedlinePlus related topics: Anesthesia Nausea and Vomiting Surgery

Drug Information available for: Sevoflurane Remifentanil hydrochloride Remifentanil Propofol

U.S. FDA Resources

Further study details as provided by Viborg Hospital:

Primary Outcome Measures:

Nausea, incidence and intensity ( VAS score )in PACU and surgical ward
Vomiting, incidence in PACU and surgical ward
Total PONV after 24 hours

Estimated Enrollment:	160
Study Start Date:	January 2002
Study Completion Date:	May 2005

Detailed Description:

Propofol and sevoflurane anaesthesia are used world wide at the anaesthetists discretion.

Propofol is superior to inhalational anaesthetics as anaesthesia for patients at risk of post operative nausea and vomiting (PONV) as PONV is diminished. However, when remifentanil is used as adjuvant to sevoflurane, the total dose of the latter is reduced.

Therefore, we wanted to investigate if sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia with emphasis on nausea, vomiting and total PONV during 24 hours.

In the post anaesthesia care unit (PACU) and in the surgical ward nausea was scored on a visual analogue score. Vomiting was registered.

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Females younger than 50 years
ASA I-II
Scheduled to gynaecological laparotomies or laparoscopies

Exclusion Criteria:

Medication known to act anti-emetic
ASA status greater than II
Malignant hyperthermia
Allergy to the drugs used.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00452855

Locations

Denmark
Viborg Hospital
Viborg, Denmark, 8800

Sponsors and Collaborators

Viborg Hospital

Nielsen, Jens OD, M.D.

Investigators

Principal Investigator:

Jens Ole Dich JO Nielsen, MD

Unaffiliated

More Information

No publications provided

Study ID Numbers:	PropSevoRemi
Study First Received:	March 26, 2007
Last Updated:	March 28, 2007
ClinicalTrials.gov Identifier:	NCT00452855 History of Changes
Health Authority:	Denmark: Ethics Committee

Keywords provided by Viborg Hospital:

Nausea
Vomiting
Post operative
Propofol remifentanil anaesthesia
Sevoflurane remifentanil anaesthesia

Additional relevant MeSH terms:

Vomiting
Signs and Symptoms, Digestive
Physiological Effects of Drugs
Hematologic Agents
Anesthetics
Sevoflurane
Signs and Symptoms
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Hypnotics and Sedatives
Nausea
Analgesics

Analgesics, Opioid
Anesthetics, Intravenous
Postoperative Nausea and Vomiting
Remifentanil
Central Nervous System Depressants
Pharmacologic Actions
Anesthetics, Inhalation
Postoperative Complications
Anesthetics, General
Platelet Aggregation Inhibitors
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 05, 2009